2023
DOI: 10.36660/abc.20220326
|View full text |Cite
|
Sign up to set email alerts
|

Diminuição dos Níveis Séricos do Receptor Solúvel da Oncostatina M (sOSMR) e Glicoproteína 130 (sgp130) em Pacientes com Doença Arterial Coronariana

Abstract: Fundamento: A oncostatina M (OSM) é uma citocina pleiotrópica que, após lesão arterial, demonstra ser expressa rapidamente. Objetivos: Correlacionar os níveis séricos da OSM, do receptor solúvel de oncostatina M (sOSMR) e da fração solúvel de glicoproteína 130 (sgp130) em pacientes com doença arterial coronariana (DAC) a parâmetros clínicos. Métodos: Os níveis de sOSMR e sgp130 foram avaliados por ELISA, enquanto os de OSM foram avaliados por Western Blot, em pacientes com SCC (n=100), pacientes com SCA (n=70)… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 38 publications
0
1
0
Order By: Relevance
“…GPCR ligand binding [60], extracellular matrix organization [61], cytokine signaling in immune system [62], interferon signaling [63], signaling by GPCR [64], neuronal system [65] and platelet activation, signaling and aggregation [66] plays an important role in the schizophrenia. Studies have revealed that SIX1 [67], VIP (vasoactive intestinal peptide) [68], GATA6 [69], FRZB (frizzled related protein) [70], CD40 [71], WT1 [72], PCDHGA3 [73], TFAP2B [74], HFE (homeostatic iron regulator) [75], NKX2-5 [76], IGFBP7 [77], HLA-F [78], CCL2 [79], COL1A2 [80], RUNX1 [81], TFF3 [82], IRX4 [83], NOS1 [84], DKK2 [85], IL18R1 [86], ADAM12 [87], NPPC (natriuretic peptide C) [88], COL1A1 [89], ABCG2 [90], SIX2 [91], CSRP1 [92], MR1 [93], NINJ2 [94], ACE (angiotensin I converting enzyme) [95], TBX1 [96], CTSC (cathepsin C) [97], DLX6 [98], KCNE1 [99], AZGP1 [100], CYP1B1 [101], PRRX1 [102], CD34 [103], A2M [104], CDKN2A [105], SERPINE1 [106], CD44 [107], FABP4 [108], ITGB3 [109], ALOX5AP [110], DAND5 [111], SFRP4 [112], RUNX2 [113], TACR3 [114], MYD88 [115], CYBA (cytochrome b-245 alpha chain) [116], STAT6 [117], FOXC1 [118], FN1 [119], TLR6 [120], CAV1 [121], RGS4 [122], TPM2 [123], TNFSF4 [124], LOX (lysyl oxidase) [125], SMOC2 [126], SPHK1 [127], FOLH1 [128], CYP2C8 [129], CD163 [130], DIRAS3 [131], OSMR (oncostatin M receptor) [132], POSTN (peri...…”
Section: Discussionmentioning
confidence: 99%
“…GPCR ligand binding [60], extracellular matrix organization [61], cytokine signaling in immune system [62], interferon signaling [63], signaling by GPCR [64], neuronal system [65] and platelet activation, signaling and aggregation [66] plays an important role in the schizophrenia. Studies have revealed that SIX1 [67], VIP (vasoactive intestinal peptide) [68], GATA6 [69], FRZB (frizzled related protein) [70], CD40 [71], WT1 [72], PCDHGA3 [73], TFAP2B [74], HFE (homeostatic iron regulator) [75], NKX2-5 [76], IGFBP7 [77], HLA-F [78], CCL2 [79], COL1A2 [80], RUNX1 [81], TFF3 [82], IRX4 [83], NOS1 [84], DKK2 [85], IL18R1 [86], ADAM12 [87], NPPC (natriuretic peptide C) [88], COL1A1 [89], ABCG2 [90], SIX2 [91], CSRP1 [92], MR1 [93], NINJ2 [94], ACE (angiotensin I converting enzyme) [95], TBX1 [96], CTSC (cathepsin C) [97], DLX6 [98], KCNE1 [99], AZGP1 [100], CYP1B1 [101], PRRX1 [102], CD34 [103], A2M [104], CDKN2A [105], SERPINE1 [106], CD44 [107], FABP4 [108], ITGB3 [109], ALOX5AP [110], DAND5 [111], SFRP4 [112], RUNX2 [113], TACR3 [114], MYD88 [115], CYBA (cytochrome b-245 alpha chain) [116], STAT6 [117], FOXC1 [118], FN1 [119], TLR6 [120], CAV1 [121], RGS4 [122], TPM2 [123], TNFSF4 [124], LOX (lysyl oxidase) [125], SMOC2 [126], SPHK1 [127], FOLH1 [128], CYP2C8 [129], CD163 [130], DIRAS3 [131], OSMR (oncostatin M receptor) [132], POSTN (peri...…”
Section: Discussionmentioning
confidence: 99%